JAFRON(SZ:300529) Sou Hu Cai Jing·2025-07-15 10:17Group 1 - The core business of the company is the research, production, and sales of biomaterials and high-tech medical devices, with major products including various blood purification devices and solutions [2] - As of the first quarter of 2025, the company reported a revenue of 548 million yuan, a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, a year-on-year decrease of 33.71%, with a gross profit margin of 80.74% [2] - The company has received multiple national and provincial recognitions, including being designated as a key high-tech enterprise under the National Torch Program and a national technology innovation demonstration enterprise [2] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 24.60, while the average PE ratio for the medical device industry is 51.83, and the industry median is 37.23 [1][3] - The total market capitalization of the company is 17.817 billion yuan, ranking it 52nd in the industry based on PE ratio [1][3] - As of the first quarter of 2025, there are 12 institutions holding shares in the company, with a total holding of approximately 62.5493 million shares valued at 1.633 billion yuan [1]